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Background: Many of the countries in the Asia Pacific Region are just initiating newborn screening programs for
selected metabolic and other congenital disorders. The present study is aimed at evaluating the congenital
hypothyroidism screening program in the Southern region of Sri Lanka in terms of coverage, effectiveness of
detecting and managing the cases.
Methods: The Newborn Screening System Database of Sri Lanka was reviewed from January 2011 to December
2012. The data of 47 babies who tested positive for hypothyroidism were analyzed.
Results: Total of 78,167 babies (99.0% of live births) were screened. Of them, 5.8% (n = 4,472) were discharged
within 12 hrs of delivery where as 58.1% (n = 44969) were discharged afterwards but within next 12 hrs (i.e., day 1).
The positive predictive value for congenital hypothyroidism (CH) was 9.0%. The incidences of primary CH among
screened infants were 1:1682. False positive rate among screened infants was maintained below 0.70%. Mean age
of serum confirmation was 23.8 (±8) days.
Conclusions: In the light of the present findings, we would suggest direct communication systems, linking newborn
screening program to the family unit. This would enhance timely follow-up for screen-positive infants and facilitate
information sharing. Establishing a program with, public-private sector partnership should be considered. Costs could
be contained if the specimen collection, its transportation and communication are carried out by this partnership
and the laboratory tests are conducted by a non-profit organization such as a University in order to achieve the goal
of universal coverage.
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Congenital hypothyroidism (CH) is the most common
preventable cause of mental retardation [1]. Screening
programs enable this potentially devastating disease to
be detected at a very early stage and allows treatment to
be started promptly, before any significant damage is
caused [2]. CH screening in newborns and early levothyr-
oxine (L-T4) substitution has dramatically improved the
outcomes of intellectual potential and linear growth in
children with CH [3-5]. Within the first few days of life,
drops of blood are collected from a newborn’s heel on to a* Correspondence: manjula.hettiarachchi@gmail.com
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article, unless otherwise stated.filter paper and are analyzed. Early detection and channel-
ing resources to provide appropriate services to the most
deserving infants is the objective of the screening pro-
gram. Every effort has been made to ensure that every
newborn receives quality appropriate services within the
scope of the screening program [6].
Many of the countries in the Asia Pacific Region are
just initiating newborn screening programs for selected
metabolic and other congenital disorders [7]. Newborn
dried blood spot screening (NDBS) as a public health
improvement strategy has existed in some countries in
the Asia Pacific since the 1960s (Australia, Japan, New
Zealand). Despite attempts over time to begin organized
newborn screening in various countries in the region, its
implementation has been slow, mainly due to economicBioMed Central Ltd. This is an Open Access article distributed under the terms
(http://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 Program indicators
2011 2012 Total
Total number of live births 38419 39285 77704
Screened infants 38248 39113 77361
Percentage of coverage 99.6% 99.6% 99.6%
Total positives 303 235 538
True positives 21 26 47
False positives 283 209 492
Positive predictive value 6.9% 11.1% 8.6%
Incidence of primary CH among screened 1:1821 1:1504 1:1682
False positive rate among screened 0.74% 0.53% 0.64%
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dorsed the introduction of screening program for CH
using the TSH assay methods (Radioimmunoassay –RIA
or Enzyme Linked Immunosorbant Assay –ELISA) in
the Southern region of the country. Program evaluation
is an important organizational practice in the public
health sector. However, it is neither practiced consist-
ently, nor is it sufficiently well-integrated into the day
to day management of most programs. Therefore, the
present study is aimed at evaluating the congenital
hypothyroidism screening program in the South of Sri
Lanka in terms of coverage, effectiveness of detection
and managing the cases.
Methods
The study was carried out through follow-up and retro-
spective approaches at the Nuclear Medicine Unit. The
study protocol received approval from the Institutional
Ethical Review Board of the Faculty of Medicine, University
of Ruhuna. The Newborn Screening program of the
Southern Province began in September 2010 with the
circular issued by the Director General of Health Ser-
vices of Sri Lanka and the circular is attached as an
Additional file 1.
The procedure followed in the hospitals is that once a
newborn assessment has been conducted mother-infant
pair is discharged from the hospital. Therefore, blood
spot collection should be carried out prior to the hospital
discharge. The cut off values for blood spot TSH used was
40.0 mIU/L upto 48 hrs (i.e., Day 2) and 20.0 mIU/L after
48 hrs of life (i.e., Day 3 onwards). These figures were
based on the analysis of pilot study [8] in the region. The
blood spot analyses were done using the IMMUCHEM™
NEONATAL TSH-MW ELISA (bulk kit −20 plates) and
RIA kits (500 tubes kit) provided by MP Biochemicals,
USA. Once a positive sample is found a repeat test was also
performed to confirm results. Then the parents were con-
tacted immediately in order to get a serum sample for the
confirmation of the disease. Both serum TSH and free thy-
roxine levels were determined in these babies using re-
spective ELISA kits provided by the MP Biochemicals,
USA. Congenital hypothyroidism was confirmed if serum
TSH >9.8 mIU/L and free thyroxine < 10 pmol/L. Then
the subjects were referred for treatment and follow up.
The Newborn Screening System Database of the NMU
(nsisd.ruh.ac.lk) was reviewed from January 2011 to
December 2012 to calculate the number of live births
and screened infants. In addition, the number of total
positives (true positives and false positives) was recorded
to calculate the positive predictive value of the screening
test. These data were used to estimate the coverage of
the program. Further, screening results including age at
screening, confirmation, and age at starting treatment
were also reviewed.Results
The public healthcare system in the Southern Province
of Sri Lanka is conducted mainly, with the services of a
Teaching Hospital, two General Hospitals, eight Base
Hospitals where board certified pediatricians are avail-
able for neonatal care. Further, there are 60 Divisional
Hospitals for maternal care with delivery facilities. Even
though the screening program began in September 2010,
the sample collection was not well established in all hos-
pitals. It took 2–3 months to streamline the process of
sample collection, transporting to the testing facility at
the Nuclear Medicine Unit and delivering the results.
Therefore, the data for the year of 2010 was not in-
cluded in this study (4680 babies were screened and 4
babies were confirmed as having primary CH out of 98
positive cases) during this period. Further, another General
Hospital adjacent to Southern Province (Monaragala) was
included into the program from February, 2011 onwards
but it was not included in the analysis (10,592 babies were
screened and 8 true positives during these 2 years.
The program indicators for Southern Province are
summarized in Table 1. We were able to achieve 99%
coverage among live births within a year of implementa-
tion and maintained it throughout the study period. By
the end of 2012, 47 true positive infants were identified
with a positive predictive value of 9.0%. The rate of
incidences of primary CH among screened infants was
1:1682. False positive rate among screened infants were
maintained below 0.70%.
Further, analyses done on sample collection and data are
summarized in Table 2. Our records indicated that 5.8%
(n = 4,472) of babies’ blood spots were collected within
12 hrs of delivery, and 58.1% (n = 44969) were collected in
the following 12 hr period (i.e., within day 1; Table 2). The
number of blood spots collected on day 2 was 18.8%
(n = 14516) and day 3 was 8.2% (n = 6315) respectively.
Only 9.2% (n = 7090) of babies’ blood spots were collected
after 72 hrs of life (i.e., from Day 4 onwards).
The sample collection ages ranged from 12 hours of
age to 83 days of age. The median age of screening
Table 2 Blood spot TSH level (mIU/L) distribution according to the date of blood spot collection
Sample collected on
< 12 hrs Day 1 Day 2 Day 3 After Day 4
(n = 4472) (n = 44969) (n = 14516) (n = 6315) (n = 7090)
Normal infants n 4359 44640 14487 6300 7037
Median 7.3 6.2 2.8 1.8 2.1
(n = 76823) Range 1.0 – 39.9 1.00 – 39.9 1.00 – 39.7 1.00 – 18.2 1.00 – 19.3
False positives n 112 301 23 15 41
Median 47.3 47.2 61.9 53.4 53.4
(n = 492) Range 40.0 – 268.7 40.0 – 319.4 40.2 – 312.5 24.7 – 121.5 20.1 – 258.4
True positives n 1 28 6 – 12
Median 230.10 191.4 204.7 – 189.3
(n = 47) Range 48.4 – 342.1 81.0 – 370.9 – 32.4 – 409.6
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In this program, the age at serum sampling (for the con-
firmatory testing) was conducted between 9.0 to 45.0 days
with a mean of 23.0 ± 8.0 days. The serum confirmation
was made before 21 days of age for 51.1% (n = 24) of the
cases. The confirmation was made between 22 days and
28 days of age for 21.3% of the cases and the confirmation
was made after 4th week of age for 27.6% (n = 13) of the
cases. Thyroxine replacement treatment commenced when
the serum confirmed results were available. The mean age
for the start of the treatment was 25.4 ± 8 days.
Discussion
Sri Lanka is the only Asian country which provides
free government funded healthcare to all its citizens.
This program came into existence in 1948 when the
country gained independence from the British Empire.
Probably as a consequence, the country has the lowest
mortality rate in the South Asian region. The country
as a whole has about 350,000 live births per year.
About 11.0% of these births are in the Southern Province
of the country. The universal coverage of the health-
care system in Sri Lanka, results in all births (99.9%)
taking place in a hospital or in a maternity home.
These facilities are staffed with trained medical practi-
tioners and public health midwives (PHM). There were
no reported home deliveries during the study period
in Southern Province.
In the developing countries, newborn screening pro-
grams are yet to achieve full nationwide coverage and
the programs in existence are generally mediocre due to
inherent weaknesses in the social service infrastructure
[9]. Nevertheless, this regional program initiated in 2010
had achieved almost 99.0% coverage within 4 months
of its implementation. This is a noteworthy accomplish-
ment for a developing country. It points to the feasibility
of conducting such a program in any other developingcountry. In developed countries, the program coverage
exceeds 99.5% [10].
The magnitude of false-positive results generated in
newborn screening programs, particularly for congenital
endocrinopathies, presents a great challenge for future
improvement of this important public health program
[11]. In this program there was a marked decrease in the
number of total positive cases (303 in 2011 to 235 in
2012) and false positive rate (0.74% to 0.53% in 2011 and
2012 respectively) among screened infants. The number
of true positive cases and consequently the incidence of
CH were increased from1:1800 in 2011 to 1:1500 in
2012. The improved performance of the test could be
attributed to experience gained in diagnosis and treat-
ments, and improved analytical methods such as radio-
immunoassay and enzyme linked immunosorbant assay.
On average we were able to identify 1 true positive result
out of 14 false-positives in 2011; and it improved to 1
positive result out of 8 false-positives in 2012. Higher
number of false positives resulted in higher number of
tests that had to be repeated, giving rise to higher costs
for the program. Ability to obtain repeated (recall) blood
specimens was unpredictable, and generally success was
much less than 100%. The negative psychological effect
of these false-positive results on parents and families is
worthy of attention [12].
The appropriate age of sampling in the newborn
screening program was a matter of debate. The optimum
age of sampling depends on many factors like the num-
ber of diseases screened for and screening method [9].
The American Academy of Pediatrics recommended that
every infant should be tested before discharge from the
nursery, optimally by 48 hours to 4 days of age. How-
ever, screening before hospital discharge or before blood
transfusion was preferable to avoid missing the diagnosis
of hypothyroidism. False-negative results may occur by
screening a very sick newborn or after blood transfusion
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Lanka, a significant problem is the early discharge of
newborns from maternity hospitals, typically before
24 hours [14]. It has been speculated that the specimens
collected in the first 24 to 48 hours of life resulted in
higher false-positive rates [15]. We were able to minimize
false-positives by using a higher cut-off value. We intro-
duced a new cut off value for samples collected prior to
72 hours (i.e., Day 3) as 40 mIU/L based on the results of
a pilot study [8]. Our decision was justified as the lowest
TSH value for a true positive baby whose blood spot col-
lected on Day 1 was 48.4 mIU/L (Table 2). If this new
value of 48.0 mIU/L is applied to the data base, 230 babies
(blood spot TSH 40.0 to 48.0 mIU/L) would not be sub-
jected to recalling, and the number of false positives of the
program would be 262 subjects. Further, the false positive
rate would be 0.34%.
The possibility of encountering false negatives with the
higher cut-off value of 40 mIU/L needs to be examined.
Unfortunately there was no follow-up study to verify the
likelihood of this occurring. Some programs have a sin-
gle TSH cutoff, while other programs have age-related
cutoffs. For example, specimens obtained in the first
24 h of life may have a TSH cutoff of >60 mU/L,
whereas specimens obtained after 72 h have a TSH cut-
off of >15 mU/L [16]. Lott et al., [17] developed age-
related reference (cutoff ) values and an algorithm to
identify babies at risk of CH using Auto DELFIA analysis
based on the manufacturer’s recommended cutoffs for
TSH. A value of ≥34.0 mIU//L was considered to be ab-
normal for babies who were 0 to 47 hrs old and the
figure of ≥28.0 mIU/ L was considered as abnormal for
babies ≥ 48 hrs old. They concluded that high TSH in
babies <24 hrs old was unreliable for screening new-
borns for hypothyroidism and that the infant should be
at least 48 hrs old for TSH and T4 testing. If not, the
cutoff value must be set to a higher value to prevent get-
ting excessive number of false-positive results; however,
this increases the chance of missing a truly hypothyroid
baby. Further, Mengreli et al., [18] reported that using a
TSH cutoff point of 10.0 mIU/L whole blood, 56 add-
itional infants with CH were diagnosed when blood sam-
ples collected on fifth day of life were analyzed using in
house RIA TSH method. It is known that changes in
threshold limits influence the number of false-positive
and false-negative results [19]. The lowering of the cut-
off point by 10 mIU/liter has increased 10 times the
number of children requiring re-evaluation [18] in whom
the diagnosis of hypothyroidism was not confirmed (false
positive results).
Re-testing raises organizational challenges to the health-
care system and also it takes an emotional toll on the par-
ents. Lowering TSH cutoffs will result in increased costs
to NBS programs (primarily through higher recall rates),yet it is not clear that the additional, milder CH cases
benefit from early detection and treatment [20]. A study
from Sweden found that cases of “subclinical CH” had an
average IQ decrement of 7 points [21]. Each one-point
drop in IQ is estimated to effect a 1% reduction in lifetime
earnings [22].
The incidence of the severe forms of thyroid dysgene-
sis, aplasia, hypoplasia/ectopia, has remained relatively
constant (1:4259), despite the lowering of the TSH cutoff
[23]. On the other hand, several studies report that de-
tection of milder forms of hypothyroidism, in particular
“thyroid-in-situ”, and, to a lesser extent, dyshormono-
genesis and ectopic thyroid glands, account for the
majority of additional cases leading to the increased inci-
dence of CH [24]. In the Quebec, Lombardy, and New
Zealand NBS programs, the incidence of more severe
forms of thyroid dysgenesis were unchanged before and
after the lowering of the TSH cutoff values [25].
As NBS programs gained experience with detection of
neonates with CH, some elected to lower the screening
TSH cutoff levels. Lowering of the TSH cutoff led to a
higher incidence of CH, primarily explained by the de-
tection of milder cases, many characterized by a eutopic,
normally formed thyroid “gland-in-situ” [24]. Detection
of milder forms of CH has refocused attention on the
initial intent of NBS, which is prevention of mental re-
tardation. Lowering of the TSH cutoff increased the
labor and economic burden of NBS programs. Moreover,
it is not clear that these milder (often transient) cases of
CH benefit from early detection and treatment [26]. The
additional cost from the increased number of retesting
amounts to about 1.8% of the screening budget [18].
Therefore, we wish to reassess the cut-off values used in
this program and more importantly enhance the analyt-
ical technique using time–tested fluoroimmunoassay in
place of RIA/ELISA.
The median age of screening sampling in the program
(1.0 day) was one of the deviations from programs of
other developing countries (mean age of 4.7 to 5.3 days)
[8,15]. In this program, the age at serum sampling
was conducted between 9.0 to 45.0 days with a mean
of 23.0 ± 8.0 days. However, other countries had much
lower period i.e., at 9.4 days (range 7–21 days) in
Alexandria [9], 15.4 days (range 6–23 days) in UAE [27].
The delay that we experienced was due to issues pertain-
ing to the recalling system in both rural and urban set-
tings. The delay in serum sampling in this program is
due to the logistics of getting the samples to the testing
facility. Further, delay in diagnosis and treatment was
seen among the group of infants whose blood spot collec-
tion has been postponed due to other factors such as col-
lecting sample after Day 4.
The implementation of this program was met with
considerable challenges due to paucity of resources.
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lamentably inadequate. Frequently laboratory services
were interrupted due to lack of reagents. A critical issue
is the lack of adequate trained personnel. In many an in-
stance a healthcare facility is manned by a single qualified
person. Hence the program is often held up if that person
happens to be to on leave. In spite of these obstacles, rec-
ognition of the immense benefit that flows from a pro-
gram such as this should inspire us to seek solutions for
assisting the most vulnerable of the citizenry.Conclusions
Efficient data collection and communication between
parents and the medical service providers can be im-
proved with help of modern technologies. To overcome
the inefficiencies of the rural postal service and the poor
transportation system, a web based tool is being consid-
ered for data collection; internet short message system
(SMS) is proposed for communication between the par-
ents and medical personnel. These measures would help
link the screening program directly to the family unit
and bring about timely follow-up of infants who prove
positive for CH and help provide remedial measures
quickly. To accomplish these endeavors, the services of
internet service providers and the mobile phone service
providers should be enlisted into the screening program.
These and other improvements for the screening pro-
gram as well as working towards the goal of achieving
nationwide coverage require devoting considerable fi-
nancial resources and time. To advance the plan of ac-
tion, establishing a program with a public-private sector
partnership should be considered. Costs could be cur-
tailed if the specimen collection, its transportation and
communication are carried out by this partnership
and the laboratory tests are conducted by a non-profit
organization such as a University. The participants will
have to pay a modest fee for this service, with subsidies
for the needy. With this approach, while tapping into effi-
ciencies of the private enterprise, the goal of universal
coverage could be achieved speedily with reduced costs.Consent
Written informed consent was obtained from the patient
for the publication of this report and any accompanying
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